Enfusion (ENFN) Projected to Post Quarterly Earnings on Tuesday

Enfusion (NYSE:ENFN - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $54.39 million for the quarter.

Enfusion (NYSE:ENFN - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Stock Performance

Shares of ENFN traded down $0.06 during trading hours on Friday, hitting $11.24. The stock had a trading volume of 970,369 shares, compared to its average volume of 1,164,913. Enfusion has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The firm has a 50-day moving average price of $10.96 and a 200 day moving average price of $9.86. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Stifel Nicolaus upped their price target on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. Finally, William Blair reissued a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $11.13.

Remove Ads

Insider Transactions at Enfusion

In other Enfusion news, CEO Oleg Movchan sold 2,771 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now owns 526,702 shares of the company's stock, valued at $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Neal Pawar sold 2,769 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the sale, the chief operating officer now owns 1,231,627 shares in the company, valued at $14,139,077.96. This trade represents a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,022 shares of company stock worth $492,706 in the last ninety days. Insiders own 36.44% of the company's stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.